Increased mitochondrial DNA deletions in substantia nigra dopamine neurons of the aged rat

Current Aging Science

Volumn 7, Issue 3, 2015, Pages 155-160

  Parkinson, Gemma M ^a,b,c   Dayas, Christopher V ^a,b,c   Smith, Doug W ^a,b,c  

^a UNIVERSITY OF NEWCASTLE   (Australia)

^b UNIVERSITY OF NEWCASTLE   (Australia)

^c HUNTER MEDICAL RESEARCH INSTITUTE   (Australia)

Author keywords

Aging; Dopamine neuron; Mitochondrial DNA deletions; Rat; Substantia nigra

Indexed keywords

MITOCHONDRIAL DNA;

AGING; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY LABELING; ARTICLE; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; GENE DELETION; LASER MICRODISSECTION; MALE; MITOCHONDRIAL GENE; MOTOR CONTROL; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; PHENOTYPE; PRIORITY JOURNAL; RAT; REAL TIME POLYMERASE CHAIN REACTION; SUBSTANTIA NIGRA; AGE; ANIMAL; CHEMISTRY; COMPARATIVE STUDY; CYTOLOGY; FISCHER 344 RAT; GENETICS; LASER CAPTURE MICRODISSECTION;

AGE FACTORS; AGING; ANIMALS; DNA, MITOCHONDRIAL; DOPAMINERGIC NEURONS; GENE DELETION; LASER CAPTURE MICRODISSECTION; MALE; RATS, INBRED F344; REAL-TIME POLYMERASE CHAIN REACTION; SUBSTANTIA NIGRA;

EID: 84928802602     PISSN: 18746098     EISSN: 18746128     Source Type: Journal    
DOI: 10.2174/1874609808666150122150850     Document Type: Article

References (50)

1. [1] Emerich DF, McDermott P, Krueger P, et al. Locomotion of aged rats: Relationship to neurochemical but not morphological changes in nigrostriatal dopaminergic neurons. Brain Res Bull 1993; 32(5): 477-86.
2. [2] Emborg ME, Ma SY, Mufson EJ, et al. Age-related declines in nigral neuronal function correlate with motor impairments in rhesus monkeys. J Comp Neurol 1998; 401(2): 253-65.
3. [3] Cham R, Perera S, Studenski SA, Bohnen NI. Striatal dopamine denervation and sensory integration for balance in middle-aged and older adults. Gait Posture 2007; 26(4): 516-25.
4. [4] van Dyck CH, Avery RA, MacAvoy MG, et al. Striatal dopamine transporters correlate with simple reaction time in elderly subjects. Neurobiol Aging 2008; 29(8): 1237-46.
5. [5] Ling ZD, Collier TJ, Sortwell CE, et al. Striatal trophic activity is reduced in the aged rat brain. Brain Res 2000; 856(1-2): 301-9.
6. [6] Haycock JW, Becker L, Ang L, Furukawa Y, Hornykiewicz O, Kish SJ. Marked disparity between age-related changes in dopamine and other presynaptic dopaminergic markers in human striatum. J Neurochem 2003; 87(3): 574-85.
7. Yurek DM, Hipkens SB, Hebert MA, Gash DM, Gerhardt GA. Age-related decline in striatal dopamine release and motoric function in brown Norway/Fischer 344 hybrid rats. Brain Res 1998 27; 791(1-2): 246-56.
8. [8] Ma SY, Ciliax BJ, Stebbins G, et al. Dopamine transporterimmunoreactive neurons decrease with age in the human substantia nigra. J Comp Neurol 1999; 409(1): 25-37.
9. [9] Chu Y, Kompoliti K, Cochran EJ, Mufson EJ, Kordower JH. Agerelated decreases in Nurr1 immunoreactivity in the human substantia nigra. J Comp Neurol 2002; 450(3): 203-14.
10. [10] Stark AK, Pakkenberg B. Histological changes of the dopaminergic nigrostriatal system in aging. Cell Tissue Res 2004; 318(1): 81-92.
11. [11] Gao J, Miao H, Xiao CH, et al. Influence of aging on the dopaminergic neurons in the substantia nigra pars compacta of rats. Curr Aging Sci 2011; 4(1): 19-24.
12. [12] Greene JG, Dingledine R, Greenamyre JT. Gene expression profiling of rat midbrain dopamine neurons: implications for selective vulnerability in parkinsonism. Neurobiol Dis 2005; 18(1): 19-31.
13. [13] Ott M, Gogvadze V, Orrenius S, Zhivotovsky B. Mitochondria, oxidative stress and cell death. Apoptosis 2007; 12(5): 913-22.
14. [14] Meiser J, Weindl D, Hiller K. Complexity of dopamine metabolism. Cell Commun Signal 2013; 11(1): 34.
15. [15] Venkateshappa C, Harish G, Mythri RB, Mahadevan A, Bharath MM, Shankar SK. Increased oxidative damage and decreased antioxidant function in aging human substantia nigra compared to striatum: implications for Parkinson's disease. Neurochem Res 2012; 37(2): 358-69.
16. [16] Anderson S, Bankier AT, Barrell BG, et al. Sequence and organization of the human mitochondrial genome. Nature 1981; 290(5806): 457-65.
17. [17] Richter C, Park JW, Ames BN. Normal oxidative damage to mitochondrial and nuclear DNA is extensive. Proc Natl Acad Sci USA 1988; 85(17): 6465-7.
18. [18] Chen D, Cao G, Hastings T, et al. Age-dependent decline of DNA repair activity for oxidative lesions in rat brain mitochondria. J Neurochem 2002; 81(6): 1273-84.
19. [19] Imam SZ, Karahalil B, Hogue BA, Souza-Pinto NC, Bohr VA. Mitochondrial and nuclear DNA-repair capacity of various brain regions in mouse is altered in an age-dependent manner. Neurobiol Aging 2006; 27(8): 1129-36.
20. [20] Rossignol R, Faustin B, Rocher C, Malgat M, Mazat JP, Letellier T. Mitochondrial threshold effects. Biochem J 2003; 370(Pt 3): 751-62.
21. [21] Trifunovic A, Wredenberg A, Falkenberg M, et al. Premature ageing in mice expressing defective mitochondrial DNA polymerase. Nature 2004; 429(6990): 417-23.
22. [22] Kujoth GC, Hiona A, Pugh TD, et al. Mitochondrial DNA mutations, oxidative stress, and apoptosis in mammalian aging. Science 2005; 309(5733): 481-4.
23. [23] Vermulst M, Wanagat J, Kujoth GC, et al. DNA deletions and clonal mutations drive premature aging in mitochondrial mutator mice. Nat Genet 2008; 40(4): 392-4.
24. [24] Perier C, Bender A, Garcia-Arumi E, et al. Accumulation of mitochondrial DNA deletions within dopaminergic neurons triggers neuroprotective mechanisms. Brain 2013; 136(Pt 8): 2369-78.
25. [25] Bender A, Krishnan KJ, Morris CM, et al. High levels of mitochondrial DNA deletions in substantia nigra neurons in aging and Parkinson disease. Nat Genet 2006; 38(5): 515-7.
26. [26] Kraytsberg Y, Kudryavtseva E, McKee AC, Geula C, Kowall NW, Khrapko K. Mitochondrial DNA deletions are abundant and cause functional impairment in aged human substantia nigra neurons. Nat Genet 2006; 38(5): 518-20.
27. [27] Bender A, Schwarzkopf RM, McMillan A, et al. Dopaminergic midbrain neurons are the prime target for mitochondrial DNA deletions. J Neurol 2008; 255(8): 1231-5.
28. [28] Krishnan KJ, Ratnaike TE, De Gruyter HL, Jaros E, Turnbull DM. Mitochondrial DNA deletions cause the biochemical defect observed in Alzheimer's disease. Neurobiol Aging 2012; 33(9): 2210-4.
29. Bua E, Johnson J, Herbst A, et al. Mitochondrial DNA-deletion mutations accumulate intracellularly to detrimental levels in aged human skeletal muscle fibers. Am J Hum Genet 2006; 79(3): 469-80.
30. [30] Herbst A, Pak JW, McKenzie D, Bua E, Bassiouni M, Aiken JM. Accumulation of mitochondrial DNA deletion mutations in aged muscle fibers: evidence for a causal role in muscle fiber loss. J Gerontol A Biol Sci Med Sci 2007; 62(3): 235-45.
31. [31] He L, Chinnery PF, Durham SE, et al. Detection and quantification of mitochondrial DNA deletions in individual cells by real-time PCR. Nucleic Acids Res 2002; 30(14): e68.
32. [32] Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc 2008; 3(6): 1101-8.
33. [33] Brown AL, Smith DW. Improved RNA preservation for immunolabeling and laser microdissection. RNA 2009; 15(12): 2364-74.
34. [34] Brown AL, Day TA, Dayas CV, Smith DW. Purity and enrichment of laser-microdissected midbrain dopamine neurons. Biomed Res Int 2013; 2013: 747938.
35. [35] Krishnan KJ, Bender A, Taylor RW, Turnbull DM. A multiplex real-time PCR method to detect and quantify mitochondrial DNA deletions in individual cells. Anal Biochem 2007; 370(1): 127-9.
36. [36] Elstner M, Muller SK, Leidolt L, et al. Neuromelanin, neurotransmitter status and brainstem location determine the differential vulnerability of catecholaminergic neurons to mitochondrial DNA deletions. Mol Brain 2011; 4: 43.
37. [37] Bjorklund A, Dunnett SB. Dopamine neuron systems in the brain: an update. Trends Neurosci 2007; 30(5): 194-202.
38. [38] Fearnley JM, Lees AJ. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 1991; 114 (Pt 5): 2283-301.
39. [39] Guo X, Kudryavtseva E, Bodyak N, et al. Mitochondrial DNA deletions in mice in men: substantia nigra is much less affected in the mouse. Biochim Biophys Acta 2010; 1797(6-7): 1159-62.
40. [40] Liang CL, Wang TT, Luby-Phelps K, German DC. Mitochondria mass is low in mouse substantia nigra dopamine neurons: Implications for Parkinson's disease. Exp Neurol 2007; 203(2): 370-80.
41. [41] Cahif A, Parkinson GM, Dayas CV, Smith DW. Characterisation of mitochondrial DNA deletions by long-PCR in central nervous system regions of young, middle- and old-aged rats. Curr Aging Sci 2013; 6(3): 232-8.
42. [42] DeMattei M, Levi AC, Fariello RG. Neuromelanic pigment in substantia nigra neurons of rats and dogs. Neurosci Lett 1986; 72(1): 37-42.
43. [43] Herrero MT, Hirsch EC, Kastner A, et al. Does neuromelanin contribute to the vulnerability of catecholaminergic neurons in monkeys intoxicated with MPTP? Neuroscience 1993; 56(2): 499-511.
44. [44] Zhang W, Phillips K, Wielgus AR, et al. Neuromelanin activates microglia and induces degeneration of dopaminergic neurons: implications for progression of Parkinson's disease. Neurotox Res 2011; 19(1): 63-72.
45. [45] Shamoto-Nagai M, Maruyama W, Yi H, et al. Neuromelanin induces oxidative stress in mitochondria through release of iron: mechanism behind the inhibition of 26S proteasome. J Neural Transm 2006; 113(5): 633-44.
46. [46] Zucca FA, Bellei C, Giannelli S, et al. Neuromelanin and iron in human locus coeruleus and substantia nigra during aging: consequences for neuronal vulnerability. J Neural Transm 2006; 113(6): 757-67.
47. [47] Zecca L, Stroppolo A, Gatti A, et al. The role of iron and copper molecules in the neuronal vulnerability of locus coeruleus and substantia nigra during aging. Proc Natl Acad Sci USA 2004; 101(26): 9843-8.
48. [48] Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003; 24(2): 197-211.
49. [49] Bowenkamp KE, Ujhelyi L, Cline EJ, Bickford PC. Effects of intra-striatal GDNF on motor coordination and striatal electrophysiology in aged F344 rats. Neurobiol Aging 2000; 21(1): 117-24.
50. [50] Fox CM, Gash DM, Smoot MK, Cass WA. Neuroprotective effects of GDNF against 6-OHDA in young and aged rats. Brain Res 2001; 896(1-2): 56-63.